Galapagos’ Acquisition of CellPoint

Wilson Sonsini Goodrich & Rosati advised CellPoint on the deal. Walder Wyss has advised +ND Capital, while Baker McKenzie advised CellPoint and AboundBio.

Galapagos, a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines, announced it has signed a definitive agreement for an all-cash acquisition of CellPoint for an upfront payment of €125 million, with additional milestone payments up to €100 million. CellPoint is dedicated to developing CAR-T therapies at the point-of-care, making these therapies more affordable and accessible to patients.

As sole venture investor in CellPoint, a company dedicated to developing CAR-T therapies at the point-of-care, the sale underlines +ND Capital’s success in Europe, being its second exit after Arctos Medical sale to Novartis.

Through the acquisition of CellPoint, Galapagos gains access to an innovative, scalable, decentralized, and automated point-of-care cell therapy supply model. Developed through a strategic collaboration with Lonza, the supply model offers the potential for efficient, seven-day delivery of CAR-T therapies and avoids complex logistics, thereby addressing important limitations of current CAR-T treatments. The proprietary platform consists of CellPoint’s end-to-end xCellit workflow management and monitoring software and Lonza’s Cocoon® system, a closed, automated manufacturing platform for cell and gene therapies.

The Wilson Sonsini team that advised CellPoint on the transaction included: Lou Lieto (Picture), Angel Wang, Moonkyoung Um, Farah Gerdes and Amy Foust.

The Walder Wyss team was led by Luc Defferrard (Partner, Corporate/M&A) and included Michael Kündig (Senior Associate, Corporate/M&A) and Alice Vorburger (Associate, Corporate/M&A).

The Baker McKenzie team that advised on the CellPoint transaction was led by Rebecca Kuijpers-Zimmerman (Amsterdam) and Roel Meers (Brussels), supported by Casper Henschen (Amsterdam), Oren Livne (New York) and Els Janssens (Belgium). 
The Baker McKenzie team that advised on the AboundBio transaction was led by Olivia Tyrrell (Chicago) and Michelle Heisner (New York).

Involved fees earner: Michelle Heisner – Baker McKenzie; Casper Henschen – Baker McKenzie; Els Janssens – Baker McKenzie; Rebecca Kuijpers-Zimmerman – Baker McKenzie; Oren Livne – Baker McKenzie; Roel Meers – Baker McKenzie; Luc Defferrard – Walder Wyss Ltd.; Michael Kündig – Walder Wyss Ltd.; Alice Vorburger – Walder Wyss Ltd.; Amy Foust – Wilson Sonsini Goodrich & Rosati; Farah Gerdes – Wilson Sonsini Goodrich & Rosati; Louis Lieto – Wilson Sonsini Goodrich & Rosati; Moonkyoung Um – Wilson Sonsini Goodrich & Rosati; Angel Wang – Wilson Sonsini Goodrich & Rosati;

Law Firms: Baker McKenzie; Walder Wyss Ltd.; Wilson Sonsini Goodrich & Rosati;

Clients: +ND Capital; AboundBio; CellPoint ;

Martina Bellini

Author: Martina Bellini